登录 | 注册    关注公众号  
搜索

CEACAM-6信息

英文名称:Carcinoembryonic antigen related cell adhesion molecule 6
中文名称:癌胚抗原相关细胞粘附分子6
靶点别称:CEACAM6,CD66c,NCA,Carcinoembryonic Antigen Related Cell Adhesion Molecule 6,Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6 (Non-Specific Cross Reacting Antigen),Normal Cross-Reacting Antigen,Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6,Non-Specific Crossreacting Antigen,Cluster Of Differentiation 66c,CD66c Antigen,CEAL,CEA Cell Adhesion Molecule 6
上市药物数量:0
临床药物数量:2
最高研发阶段:临床前

CEACAM-6 分子别名

CEACAM6,CD66c,CEAL,NCA

CEACAM-6 分子背景

Carcinoembryonic antigen-related cell adhesion molecule 6 (non-specific cross reacting antigen) (CEACAM6) is also known as CD66c (Cluster of Differentiation 66c), CEAL, NCA, and is one of seven human CEACAM family members within the immunoglobulin superfamily. In humans, CEACAMs include type I transmembrane proteins (CEACAM1, CEACAM3, and CEACAM4) and GPI-linked molecules (CEACAM5 through CEACAM8). There is no human CEACAM2. CEACAM 6 contains one N-terminal V-type Ig-like domain (N domain), followed by two C2-type Ig-like domains. It shows considerable glycosylation, including (sialyl) LewisX, which mediates binding to E-selectin, galectins and some bacterial fimbrae. CEACAM-6 is expressed by granulocytes and their progenitors. It is also expressed by epithelia of various organs and is upregulated in pancreatic and colon adenocarcinomas, as well as hyperplastic polyps. Resistance to adhesion-related apoptosis in tumor cells is conferred in the condition of CEACAM6 overexpression.

CEACAM-6 前沿进展

CEACAM-6临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
L-DOS-47 L-DOS-47 Helix Biopharma 详情
NEO-201 NEO-201 Precision Biologics, 美国国立癌症研究所 详情

消息提示

请输入您的联系方式,再点击提交!

确定